
TLSI Stock Forecast & Price Target
TLSI Analyst Ratings
Bulls say
TriSalus Life Sciences is well positioned because its TriNav PEDD platform addresses a real clinical and economic gap: it improves selective delivery in a market where roughly 90% of liver embolization procedures still rely on standard catheters, while 2026 evidence showed better tumor targeting, higher response rates, and about $7,700 of avoided billed charges per patient. The reimbursement backdrop is also improving, with permanent HCPCS codes and, effective January 1, 2027, higher Medicare payment rates and an office-based lab payment that should strengthen provider economics and expand access, supporting adoption from a current roughly 10% liver share. Growth optionality is substantial, since TriNav Advance broadens access to smaller vessels and adjacent indications could expand the company’s addressable market from roughly $480M in liver to nearly $2.5B, while 2025 revenue of $45.2M and FY26 guidance of $54M-$57M show an already scaling commercial base.
Bears say
TriSalus Life Sciences is facing a weaker-than-expected commercial ramp as 3Q26 revenue of $12.9M missed consensus and forced FY26 guidance down to $46M-$48M from $54M-$57M, reflecting slower productivity in expansion territories and a delayed benefit from TriNav Advance. The business remains highly concentrated in TriNav, so adoption risk, annual reimbursement resets, and ongoing 510(k) regulatory uncertainty create a fragile revenue base, while the evidence for PEDD is still largely retrospective and single-center. With cash of $41.1M against $32.4M of long-term debt and a net loss of $0.15 per diluted share in 3Q26, the company may need additional capital in mid-2027, leaving dilution risk an important overhang.
This aggregate rating is based on analysts' research of TriSalus Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
TLSI Analyst Forecast & Price Prediction
Start investing in TLSI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About TriSalus Life Sciences Inc (TLSI) Forecast
TLSI Analyst Forecast & Price Prediction
Start investing in TLSI
Order type
Buy in
Order amount
Est. shares
0 shares